Despite this controversy and due to the significant impact of anti-Her-2 treatment on breast cancer, several groups have studied the role of trastuzumab or pertuzumab in Her-2 expressing EOC patients [4,5]. The gene discussed is ERBB2; the disease is breast carcinoma.